The acquisition is small relative to Merit's $5.6B market cap and is not expected to materially affect near-term financials. Monitor future quarters for revenue contribution from Solo Pace products and any updates on adoption in the TAVR market.
Price Chart
Executive Summary
Merit Medical Systems acquired all remaining equity of Solo Pace for approximately $45 million, adding temporary pacing technology for TAVR procedures. The deal expands Merit's Cardiac Therapies platform and is expected to be immaterial to 2026 financials and slightly accretive to non-GAAP earnings in 2027.
Key Financial Metrics
Key Facts
- Merit acquired Solo Pace on October 13, 2026 for approximately $45 million.
- Merit previously owned about 18% of Solo Pace and had invested $5 million since January 2023.
- Solo Pace's SOLO PACE CONTROL and FUSION systems are used in TAVR procedures.
- The acquisition is projected to be immaterial to Merit's full-year 2026 revenue and earnings.
- For 2027, the acquisition is projected to be slightly accretive to non-GAAP net income and EPS.
- Solo Pace received FDA 510(k) clearance for SOLO PACE FUSION in April 2025 and commercial release in March 2026.
Financial Impact
Purchase consideration of $45 million; immaterial to 2026 results; slightly accretive to non-GAAP EPS in 2027 with ~$1.5M lower interest income and ~$3.2M non-cash transaction expenses.
Risk Factors
- Integration risks and ability to achieve projected financial benefits.
- Market adoption of Solo Pace technology may be slower than expected.
- Potential for competitive developments in the TAVR pacing space.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3391814 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 29, 2026 3d ago | 8-K | No price | awaiting T+60 | awaiting T+60 | No price |
Oct 29, 2026 3d ago | Press Release | $93.39 | awaiting T+60 | awaiting T+60 | $86.24 (−7.66%) |
Oct 29, 2026 3d ago | Press Release | $93.39 | awaiting T+60 | awaiting T+60 | $86.24 (−7.66%) |
Oct 27, 2026 4d ago | Institutional Cluster | $92.21 | awaiting T+60 | awaiting T+60 | $86.24 (−6.47%) |
Jul 2, 2026 17w ago | Press Release | $71.09 $87.00 | ▲ +22.38% | ▲ +18.81% | $86.24 (+21.31%) |
May 5, 2026 25w ago | Insider Cluster | $60.44 $83.35 | ▲ +37.91% | ▲ +35.17% | $86.24 (+42.69%) |
May 5, 2026 25w ago | Insider Cluster | $60.44 $83.35 | ▲ +37.91% | ▲ +35.17% | $86.24 (+42.69%) |
Apr 30, 2026 26w ago | Press Release | $62.01 $78.29 | ▲ +26.25% | ▲ +23.18% | $86.24 (+39.07%) |
Apr 16, 2026 28w ago | Court Ruling | $70.10 $73.26 | ▲ +4.51% | ▼ −2.54% | $86.24 (+23.02%) |
Apr 13, 2026 28w ago | 8-K | $70.54 $71.46 | ▲ +1.30% | ▼ −7.22% | $86.24 (+22.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers